Notice of deficiency with nasdaq continued listing requirements

Zurich, switzerland / accesswire / january 12, 2024 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that on january 9, 2024, it received a letter from the listing qualifications staff of the nasdaq stock market ("nasdaq") notifying the company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the nasdaq capital market.
NLSP Ratings Summary
NLSP Quant Ranking